Integrated Investment Consultants LLC Trims Stock Position in Sanofi (NASDAQ:SNY)

Integrated Investment Consultants LLC trimmed its holdings in shares of Sanofi (NASDAQ:SNY) by 10.2% in the third quarter, HoldingsChannel reports. The firm owned 4,855 shares of the company’s stock after selling 550 shares during the period. Integrated Investment Consultants LLC’s holdings in Sanofi were worth $280,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the stock. POM Investment Strategies LLC purchased a new position in Sanofi in the 2nd quarter valued at about $25,000. Northwest Investment Counselors LLC purchased a new position in shares of Sanofi during the third quarter valued at approximately $29,000. Concord Wealth Partners lifted its stake in shares of Sanofi by 157.8% during the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after buying an additional 363 shares during the period. Arrow Financial Corp acquired a new stake in Sanofi during the second quarter worth approximately $35,000. Finally, Fortitude Family Office LLC grew its stake in Sanofi by 708.6% in the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after acquiring an additional 659 shares during the period. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Price Performance

SNY stock opened at $48.28 on Friday. The company has a market cap of $122.53 billion, a PE ratio of 24.63, a price-to-earnings-growth ratio of 1.22 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The stock has a 50-day moving average price of $53.70 and a two-hundred day moving average price of $52.15. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97.

Sanofi (NASDAQ:SNY) last issued its earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter in the previous year, the business earned $2.55 EPS. The company’s revenue for the quarter was up 12.3% on a year-over-year basis. As a group, research analysts predict that Sanofi will post 4.29 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on SNY shares. Argus raised their price objective on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th. Finally, Citigroup raised shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.